***Background.*** Incidence of invasive pneumococcal disease (IPD) dramatically declined among children and adults after 7-valent pneumococcal conjugate vaccine (PCV7) introduction for children in 2000. In February 2010, 13-valent pneumococcal conjugate vaccine (PCV13) replaced PCV7. We evaluated PCV13 impact on IPD rates among children and adults.

***Methods.*** IPD cases (isolation of pneumococcus from sterile sites) were identified through 10 Active Bacterial Core surveillance (ABCs) sites during July 2006--June 2013. Isolates were serotyped at reference laboratories. To distinguish the incremental effect of PCV13, we focused on the 5 serotypes (PCV5 types) not affected by PCV7. We used pre-PCV13 observed cases in time-series models to forecast post-PCV13 incidence in the absence of PCV13. PCV13 impact was the difference between forecasted and observed incidence.

***Results.*** ABCs identified 3,355 and 21,747 IPD cases among children and adults, respectively; 90% of isolates had serotyping results. Incidence of PCV5-type IPD declined in all age groups after PCV13 introduction with the largest decline among children \<5 years (table). Reductions in PCV5-type IPD were driven by serotypes 19A and 7F. No significant increase was seen in non-PCV13 serotypes, except among 50--64 year olds in 2012--2013 (percent change, 26; 95% interval estimate (IE): 13--44).

###### 

Changes in incidence of PCV5-type IPD, by age

  Age group (years)   Percent Change Compared toIncidence Expected in Absence of PCV13 (95% IE)                    
  ------------------- --------------------------------------------------------------------------- ---------------- ----------------
  \<5                 -66 (-70, -61)                                                              -88 (-89, -86)   -93 (-94, -91)
  5--17               -35 (-45, -21)                                                              -59 (-66, -48)   -75 (-80, -67)
  18--49              -33 (-38, -26)                                                              -64 (-68, -60)   -72 (-75, -69)
  50--64              -23 (-28, -18)                                                              -54 (-57, -50)   -62 (-65, -59)
  65+                 -23 (-31, -13)                                                              -46 (-52, -39)   -58 (-64, -52)

***Conclusion.*** Dramatic reductions in PCV5-type IPD were evident among children and adults after 3 years of PCV13 use. Continued surveillance is needed to monitor for serotype replacement.
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